Real world incidence and management of adverse events in patients with HR+, HER2− metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting-Reference-Cited by-同舟云学术

Real world incidence and management of adverse events in patients with HR+, HER2− metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting

Published:2022-05-13 Issue:8 Volume:38 Page:1319-1331
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Price Gregory L.¹,Sudharshan Lavanya²,Ryan Paula³,Rajkumar Jonathan²,Sheffield Kristin M.¹,Nash Smyth Emily¹,Morato Guimaraes Claudia¹,Rybowski Sarah¹,Cuyun Carter Gebra¹,Gathirua-Mwangi Wambui Grace¹,Huang Yu-Jing¹^ORCID

Affiliation:

1. Eli Lilly and Company, Indianapolis, IN, USA

2. McKesson Life Sciences, The Woodlands, TX, USA

3. Texas Oncology – The Woodlands, The Woodlands, TX, USA

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2073122

Reference46 articles.

1. American Cancer Society. Cancer facts and figures. Atlanta (GA): American Cancer Society, Inc; 2021.

2. Quality of life outcomes in patients with breast cancer

3. Depression, quality of life and breast cancer: a review of the literature

4. Extending Survival with Chemotherapy in Metastatic Breast Cancer

5. National Cancer Institute. Surveillance, epidemiology and end of results program. Female breast cancer. (accessed 2021 Sep 30). Available from: https://seer.cancer.gov/statfacts/html/breast.html

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacodynamic characteristics, safety profile, and interactions of CDK4/6 inhibitors (CDK4/6i) in HR+/HER2– advanced/metastatic breast cancer;European Journal of Oncology Pharmacy;2024-04

2. A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases;International Journal of Clinical Pharmacy;2024-01-19

3. Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending;BMJ Oncology;2024-01

4. Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer;Biomedicine & Pharmacotherapy;2023-11

5. A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of the two real-world databases;2023-10-10